Replies to post #158679 on NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

If control does 20 months and DCVax does 28 months then, with 233 events what would the p value would be instead of 0.42.

It would be about 0.015
(assuming proportional hazards)

And I have reason to believe the control arm (as you note above) will perform even better than the ACT IV trial (who were all EGFR+).

Why? Are you suggesting that GBM patients with EGFRv3 expression don't fare as well when compared to other GBM subtypes?

Yes, I have reason to believe it is a negative prognostic indicator. (Just saw, an albeit obscure, paper recently published demonstrating that via a metanalysis). And Celdex had long been saying EGFRv3 was a negative prognostic factor as well.